Conti V.R., and McQuitty C. Vasodilatation and cardiopulmonary bypass: The role of bradykinin and the pulmonary vascular endothelium. Chest 120 (2001) 1759-1761
Cremer J., Martin M., and Redl H. Systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg 61 (1996) 1714-1720
Argenziano M., Chen J.M., Choudhri A.F., et al. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent. J Thorac Cardiovasc Surg 116 (1998) 973-980
Oh Y.J., Lee J.H., Nam S.B., et al. Effects of chronic angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor treatments on neurohormonal levels and haemodynamics during cardiopulmonary bypass. Br J Anaesth 97 (2006) 792-798
Masetti P., Murphy S.F., and Kouchoukos N.T. Vasopressin therapy for vasoplegic syndrome following cardiopulmonary bypass. J Card Surg 17 (2002) 485-489
Argenziano M., Choudhri A.F., Oz M.C., et al. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 96 (1997) 286-290
Takewa Y., Tatsumi E., Taenaka Y., et al. Hemodynamic effects of prostaglandins and catecholamines in graded reduction of pulmonary flow during venoarterial bypass in awake goats. ASAIO J 45 (1999) 79-82
Takewa Y., Taenaka Y., Tatsumi E., et al. Prostaglandin synthesis inhibitor affects humoral conditions and oxygen metabolism during normothermic cardiopulmonary bypass. Artif Organs 26 (2002) 676-681
Sato K., Takewa Y., Taenaka Y., et al. Prostaglandin synthesis inhibitor prevents hypotension without impairing gut perfusion during normothermic cardiopulmonary bypass. ASAIO J 48 (2002) 503-507
Takewa Y., Seki T., Tatsumi E., et al. Prostaglandin synthesis inhibitor improves hypotension during normothermic cardiopulmonary bypass. ASAIO J 47 (2001) 673-676
Shaer A.J. Inherited primary renal tubular hypokalemic alkalosis: A review of Gitelman and Bartter syndromes. Am J Med Sci 322 (2001) 316-332
Bettinelli A., Vezzoli G., Colussi G., et al. Genotype-phenotype correlations in normotensive patients with primary renal tubular hypokalemic metabolic alkalosis. J Nephrol 11 (1998) 61-69
Bartter F.C. Bartter's syndrome: A disorder of vascular reactivity. Hypertension 3 (1981) 69-73
Guay-Woodford L.M. Bartter syndrome: Unraveling the pathophysiological enigma. Am J Med 105 (1998) 151-161
Malafronte C., Basa N., Tedeschi S., et al. Cardiac arrythmias due to severe hypokalemia in a patient with classic Bartter disease. Pediatr Nephrol 19 (2004) 1413-1415
Haas N.A., Nossal R., Schneider C.H., et al. Successful management of an extreme example of neonatal hyperprostaglandin E syndrome (Bartter's syndrome) with the new cyclooxygenase-2 inhibitor rofecoxib. Pediatr Crit Care Med 4 (2003) 249-251
Calò L., Davis P.A., and Semphicini A. Regulation of vascular tone in Bartter's and Gitelman's syndromes. Crit Rev Clin Lab Sci 37 (2000) 503-523
Calò L., Ceolotto G., Milani M., et al. Abnormalities of Gq mediated cell signaling in Bartter's and Gitelman's syndromes. Kidney Int 60 (2001) 882-889
Calò L. Vascular tone control in humans: insights from studies in Bartter's/Gitelman's syndromes. Kidney Int 69 (2006) 963-966
Brooks P.M. Nonsteroidal anti-inflammatory drugs. In: Bowdle T.A., Horita A., and Kharasch E.D. (Eds). The Pharmacologic Basis of Anesthesiology (1994), Churchill Livingstone, New York, NY 669-688
Lanas A., Garcia-Rodriguez L.A., Arroyo M.T., et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55 (2006) 1731-1738
Huerta C., Castellsague J., Varas-Lorenzo, et al. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis 45 (2005) 531-539
